Chimeric Therapeutics (ASX:CHM) EV-to-EBIT : -1.08 (As of Jun. 09, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Chimeric Therapeutics's Enterprise Value is A$11.14 Mil. Chimeric Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-10.30 Mil. Therefore, Chimeric Therapeutics's EV-to-EBIT for today is -1.08.

The historical rank and industry rank for Chimeric Therapeutics's EV-to-EBIT or its related term are showing as below:

ASX:CHM' s EV-to-EBIT Range Over the Past 10 Years
Min: -5.1 Med: 0 Max: 0.4
Current: -1

During the past 3 years, the highest EV-to-EBIT of Chimeric Therapeutics was 0.40. The lowest was -5.10. And the median was 0.00.

ASX:CHM's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 9.8 vs ASX:CHM: -1.00

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Chimeric Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was A$21.88 Mil. Chimeric Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-10.30 Mil. Chimeric Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -47.07%.

Chimeric Therapeutics EV-to-EBIT Historical Data

The historical data trend for Chimeric Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics EV-to-EBIT Chart

Chimeric Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

EV-to-EBIT

-4.87

-1.37

-0.69

Chimeric Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial			-	-1.37	-	-0.69	-

Competitive Comparison of Chimeric Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Chimeric Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimeric Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's EV-to-EBIT falls into.

Chimeric Therapeutics EV-to-EBIT Calculation

Chimeric Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	11.141	/	-10.298
	=	-1.08

Chimeric Therapeutics's current Enterprise Value is A$11.14 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Chimeric Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-10.30 Mil.

Chimeric Therapeutics (ASX:CHM) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Chimeric Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-10.298	/	21.879435
	=	-47.07 %

Chimeric Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was A$21.88 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Chimeric Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-10.30 Mil.

Chimeric Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics (ASX:CHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

CHMMF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.chimerictherapeutics.com

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines